CompletedEUCTR 2018-003825-27
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
This historical record does not confirm current site availability.
Historical research recordAges 18–55Multiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Bentonville, United States · Culver City, United States and 55 more locationsSee all locations and recruitment
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: November 15, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 195
- Sponsor
- Biogen Idec Research Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Germany, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- EUCTR 2018-003825-27
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Recruitment & locations
CompletedBentonville, United States · Culver City, United States · Garden Grove, United States
54 more locations
- Lemon Grove, United States
- Long Beach, United States
- Montclair, United States
- Oceanside, United States
- Pico Rivera, United States
- San Diego, United States
- San Rafael, United States
- Torrance, United States
- New Haven, United States
- Lauderhill, United States
- Miami, United States
- Tampa, United States
- Atlanta, United States
- Augusta, United States
- Decatur, United States
- Chicago, United States
- Hoffman Estates, United States
- Springfield, United States
- Gaithersburg, United States
- Grand Rapids, United States
- Flowood, United States
- St Louis, United States
- Berlin, United States
- Buffalo, United States
- Cedarhurst, United States
- Rochester, United States
- Columbus, United States
- North Canton, United States
- Richardson, United States
- San Antonio, United States
- Kirkland, United States
- Bad Homburg, Germany
- Frankfurt am Main, Germany
- Westerstede, Germany
- Leipzig, Germany
- Anan-shi, Japan
- Ichikawa-shi, Japan
- Kashihara-shi, Japan
- Kawasaki-shi, Japan
- Kita-gun, Japan
- Kodaira-shi, Japan
- Kumagaya-shi, Japan
- Takasaki-shi, Japan
- Yokosuka-shi, Japan
- Santander, Spain
- Majadahonda, Spain
- Oviedo, Spain
- Barcelona, Spain
- Madrid, Spain
- Salamanca, Spain
- Seville, Spain
- Oxford, United Kingdom
- Lyne, United Kingdom
- London, United Kingdom
Registry details
Original registry record (opens in a new tab)Historical country statuses
- Germany — Completed
- United Kingdom — GB - no longer in EU/EEA
Questions about this study
Who is behind this study?
The study sponsor is Biogen Idec Research Limited.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
NCT0115735118F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
NCT06880328